| Literature DB >> 28477669 |
Mark A Underwood1, Kristin Sohn2.
Abstract
Colonization of the extremely preterm infant's gastrointestinal tract and skin begins in utero and is influenced by a variety of factors, the most important including gestational age and environmental exposures. The composition of the intestinal and skin microbiota influences the developing innate and adaptive immune responses with short-term and long-term consequences including altered risks for developing necrotizing enterocolitis, sepsis, and a wide variety of microbe-related diseases of children and adults. Alteration of the composition of the microbiota to decrease disease risk is particularly appealing for this ultra-high-risk cohort that is brand new from an evolutionary standpoint.Entities:
Keywords: Dysbiosis; Intestinal tract; Late-onset sepsis; Microbiota; Necrotizing enterocolitis; Oral cavity; Skin
Mesh:
Substances:
Year: 2017 PMID: 28477669 PMCID: PMC6361543 DOI: 10.1016/j.clp.2017.01.005
Source DB: PubMed Journal: Clin Perinatol ISSN: 0095-5108 Impact factor: 3.430
Key bacterial taxa in the preterm infant
| Phylum | Class | Order | Family | Genus |
|---|---|---|---|---|
| Firmicutes | Bacilli | Bacillales | Staphylococcaceae | |
| Lactobacillales | Streptococcaceae | |||
| Enterococcaceae | ||||
| Lactobacillaceae | ||||
| Clostridia | Clostridiales | Clostridiaceae | ||
| Negativicutes | Selenomonadales | Veillonellaceae | ||
| Mollicutes | Mycoplasmatales | Mycoplasmataceae | ||
| Proteobacteria | γ-Proteobacteria | Enterobacteriales | Enterobacteriaceae | |
| Pseudomonadales | Pseudomonadaceae | |||
| Moraxellaceae | ||||
| Bacteroidetes | Bacteroidetes | Bacteroidales | Bacteroidaceae | |
| Actinobacteria | Actinobacteria | Bifidobacteriales | Bifidobacteriaceae | |
| Propionibacteriales | Propionibacteriaceae |
Microbes associated with cases or outbreaks of necrotizing enterocolitis
| Gram-Positive Bacteria | Gram-Negative Bacteria | Fungi | Viruses |
|---|---|---|---|
| Coronavirus |
Studies of the fecal microbiota before the onset of NEC (only studies that included infants with gestational age <28 weeks are included)
| Gestational Age at Birth | NEC | Controls | Meconium | Early Stools | Just Before NEC Onset | |
|---|---|---|---|---|---|---|
| De la Cochetiere et al, | 24–29 | 3 | 9 | |||
| Mai et al, | 23–29 | 9 | 9 | Firmicutes ↑ | Proteobacteria ↑ | |
| Stewart et al, | 24–28 | 7 | 21 | Coagulase-negative staphylococci ↑ | ||
| Smith et al, | 23–30 | 15 | 128 | No differences at 3 time points: 0–5 d, day 10, and day 30 | ||
| Morrow et al, | 25.5 (1.8) | 11 | 21 | Propionibacterium ↓ | Staphylococci ↑ | |
| Normann et al, | 22–25 | 10 | 16 | Trends: Enterobacteriaceae ↑ | ||
| Torrazza et al, | 27.4 (2.6) | 18 | 35 | Klebsiella-like sp ↑ | Proteobacteria ↑ | |
| Jenke et al, | 24–27 | 12 | 56 | Lactobacilli ↑ | ||
| McMurtry et al, | 27.2 (2.8) | 21 | 74 | Actinobacteria ↓ | ||
| Sim et al, | 25–28 | 12 | 36 | |||
| Zhou et al, | 24–31 | 12 | 26 | Clostridia ↑ | ||
| Heida et al, | 24–29 | 11 | 22 | |||
| Warner et al, | 26.0 (24.7–27.9) | 46 | 120 | γ-Proteobacteria ↑ | ||
| Ward et al, | 26 (23–28) | 7 | 37 | No differences in samples from days 3–16. Days 17–22: Uropathogenic
| ||
| Twin studies | ||||||
| Stewart et al, 2013 | 26–30 | 5 | 5 | |||
| Claud et al, | 1 | 1 | Proteobacteria ↑ | |||
Arrows represent significant differences in NEC compared with control specimens.
Abbreviation: NEC, necrotizing enterocolitis.
Range or mean (SD) or median (interquartile range).
The associations were most strong for infants with gestational age at birth <27 weeks with strong time-by-NEC interactions.
Unweighted summary of probiotic studies in preterm infants
| Number Enrolled | NEC Cases Stage 2 or 3 | Culture-Positive Sepsis | Deaths | |||||
|---|---|---|---|---|---|---|---|---|
| Probiotic | Control | Probiotic | Control | Probiotic | Control | Probiotic | Control | |
| 7 randomized placebo-controlled trials with 200 or more preterm infants in each arm | ||||||||
| 2520 | 2554 | 98 | 151 | 236 | 244 | 129 | 169 | |
| % of those reporting the outcome | 3.9 | 5.9 | 10 | 11 | 5.1 | 6.6 | ||
| 7 cohort studies with 200 or more preterm infants in each group | ||||||||
| 6779 | 5099 | 201 | 299 | 648 | 530 | 498 | 434 | |
| % of those reporting the outcome | 3.0 | 5.9 | 11 | 13 | 7.3 | 8.5 | ||
| 37 randomized placebo-controlled trials (includes the infants in the 7 larger trials above) | ||||||||
| 4710 | 4675 | 153 | 283 | 475 | 548 | 224 | 315 | |
| % of those reporting the outcome | 3.3 | 6.2 | 12 | 14 | 5.1 | 7.2 | ||
| 11 cohort studies (includes the infants in the 7 larger studies above) | ||||||||
| 7742 | 7592 | 224 | 408 | 737 | 667 | 556 | 493 | |
| % of those reporting the outcome | 2.9 | 5.3 | 12 | 14 | 7.7 | 9.0 | ||
Details of 33 of the randomized controlled trials and 10 of the cohort studies are presented in Tables 1 and 2 of Ref. with the additional studies in Refs.91, 92, 93, 94, 108
Randomized controlled trials evaluating probiotics published in English and specifically evaluating infants <1 kg
| Author | Country | Probiotic Species | n <1 kg | NEC Cases ≥ stage 2 | Culture + Sepsis | Deaths | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pro | Pla | Pro | Pla | Pro | Pla | Pro | Pla | |||
| Costeloe et al, | UK | 317 | 327 | 50 | 53 | 63 | 61 | 46 | 53 | |
| Kanic et al, | Slovenia | 13 | 17 | 0 | 5 | 8 | 6 | 3 | 3 | |
| Van Niekirk et al, | South Africa | 43 | 49 | 0 | 4 | – | – | 5 | 5 | |
| Sangtawesin et al, | Thailand | 3 | 4 | 1 | 1 | 2 | 1 | 0 | 0 | |
| Tewari et al, | India | 23 | 22 | 0 | 0 | 6 | 8 | 8 | 9 | |
| Oncel et al, | Turkey | 93 | 103 | 5 | 9 | 6 | 19 | 11 | 17 | |
| Patole et al, | Australia | 28 | 29 | – | – | 11 | 6 | 0 | 0 | |
| Totsu et al, | Japan | 76 | 66 | 0 | 0 | 5 | 10 | 2 | 0 | |
| Jacobs et al, | Australia + NZ | 235 | 239 | 10 | 14 | 53 | 58 | – | – | |
| Al-Hosni et al, | US | 50 | 51 | 2 | 2 | 13 | 16 | 3 | 4 | |
| Mihatsch et al, | Germany | 91 | 89 | 2 | 4 | 28 | 29 | 2 | 1 | |
| Rouge et al, | France | 16 | 22 | – | – | 12 | 14 | – | – | |
| Underwood et al, | US | 9 | 7 | 1 | 0 | 4 | 0 | 0 | 0 | |
| Lin et al, | Taiwan | 102 | 79 | 4 | 7 | 28 | 14 | 0 | 6 | |
| Wang et al, | Japan | 11 | 11 | 0 | 0 | – | – | – | – | |
| Bin-Nun et al, | Israel | 25 | 17 | 2 | 6 | 4 | 10 | 6 | 9 | |
| Total | 1140 | 1137 | 77 | 106 | 248 | 254 | 86 | 107 | ||
| Percentage of those reporting the outcome | – | – | 6.8 | 9.5 | 23 | 24 | 9.8 | 12 | ||
Abbreviations: NEC, necrotizing enterocolitis; Pla, placebo; Pro, probiotic.
Personal communication from the author.
Culture-positive sepsis at greater than 7 days of life.
In regression model, reduction of NEC significant in subgroup analysis of less than 1 kg infants (RR [relative risk] 0.73).
These infants were less than 29 weeks (birth weight <1.16 kg).
Death and NEC were significantly lower in the probiotic group for infants 500 to 750 g (P = .02).
Cohort studies evaluating probiotics published in English and specifically evaluating infants <1 kg
| Author | Country | Probiotic Species | n <1 kg | NEC Cases ≥ Stage 2 | Culture + Sepsis | Deaths | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pro | Con | Pro | Con | Pro | Con | Pro | Con | |||
| Guthman et al, | Switzerland | 238 | 250 | 6 | 16 | – | – | 16 | 26 | |
| Janvier et al, | Canada | 98 | 109 | 10 | 18 | 30 | 38 | 14 | 27 | |
| Hunter et al, | US | 79 | 232 | 2 | 35 | 18 | 72 | – | – | |
| Luoto et al, | Finland | 218 | 879 | 17 | 45 | – | – | – | – | |
| Total | 633 | 1470 | 35 | 114 | 48 | 110 | 30 | 53 | ||
| % of those reporting the outcome | – | – | 5.5 | 7.8 | 27 | 32 | 8.9 | 15 | ||
Abbreviations: Con, control; NEC, necrotizing enterocolitis; Pro, probiotic.
| Antibiotic-associated diarrhea | Traveler’s diarrhea |
| Necrotizing enterocolitis | Infectious diarrheas |
| Preterm birth | Sepsis |
| Infant colic | |
| Inflammatory bowel disease | Food and environmental allergies |
| Irritable bowel syndrome | Celiac disease |
| Obesity | Diabetes mellitus (types 1 and 2) |
| Atherosclerosis | Cancer |
| Atopic eczema | Psoriasis |
| Seborrhea | Rheumatoid arthritis |
| Alzheimer and other neurodegenerative diseases | Mood disorders, schizophrenia, and autism |